Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Digestive Diseases and Sciences
Erschienen in: Digestive Diseases and Sciences 7/2013

01.07.2013 | Case Report

Combined Hepatocellular Cholangiocarcinoma: A Case Report and Review of Literature

Erschienen in: Digestive Diseases and Sciences | Ausgabe 7/2013

Einloggen, um Zugang zu erhalten

Excerpt

The two commonly seen subtypes of primary liver cancer are hepatocellular carcinoma (HCC) and cholangiocarcinoma (CC). They both have a distinct clinico-pathologic profile. Combined hepatocellular cholangiocarcinoma (cHCC-CC) is a far more uncommon tumor with histologic evidence of both hepatocellular and biliary epithelial differentiation [1, 2]. It accounts for about 1.0–14.2 % of all primary liver cancers with incidence varying in different studies [3, 4]. The reported incidence of cHCC-CC ranges from 1.4 to 6.5 % and varies geographically [5]. In 1949, Allen and Lisa first described this entity in detail and morphologically classified into three subtypes [6]. Since then there have been a few case series and single case reports describing this malignancy. Owing to its rarity, the natural history, clinical characteristics and optimal management of cHCC-CC is not well understood. …
Literatur
1.
Goodman ZD, Ishak KG, Langloss JM, Sesterhenn IA, Rabin L. Combined hepatocellular-cholangiocarcinoma. A histologic and immunohistochemical study. Cancer. 1985;55:124–135.PubMedCrossRef
2.
[No authors listed]. Primary liver cancer in Japan. Clinicopathologic features and results of surgical treatment. Liver cancer study group of Japan. Ann Surg. 1990;211:277–287.
3.
Jarnagin WR, Weber S, Tickoo SK, et al. Combined hepatocellular and cholangiocarcinoma: Demographic, clinical, and prognostic factors. Cancer. 2002;94:2040–2046.PubMedCrossRef
4.
Ishak KG, Anthony PP, Sobin LH. Histological Typing of the Liver. International Histological Classification of Tumours. WHO. 2nd ed. Hong Kong: Springer; 1994.
5.
Panjala C, Senecal DL, Bridges MD, et al. The diagnostic conundrum and liver transplantation outcome for combined hepatocellular-cholangiocarcinoma. Am J Transplant. 2010;10:1263–1267.PubMedCrossRef
6.
Allen RA, Lisa J. Combined liver cell and bile duct carcinoma. Am J Pathol. 1949;25:647–655.PubMed
7.
Wells H. Primary carcinoma of the liver. Am J Sci. 1903;126:403–417.CrossRef
8.
The Liver Cancer Study Group of Japan. The general rules for the clinical and pathological study of primary liver cancer. Jpn J Surg. 1989;19:98–129.CrossRef
9.
Lee JH, Chung GE, Yu SJ, et al. Long-term prognosis of combined hepatocellular and cholangiocarcinoma after curative resection comparison with hepatocellular carcinoma and cholangiocarcinoma. J Clin Gastroenterol. 2011;45:69–75.PubMed
10.
Maeda T, Adachi E, Kajiyama K, Sugimachi K, Tsuneyoshi M. Combined hepatocellular and cholangiocarcinoma: Proposed criteria according to cytokeratin expression and analysis of clinicopathologic features. Hum Pathol. 1995;26:956–964.PubMedCrossRef
11.
Leong AS, Sormunen RT, Tsui WM, Liew CT. Hep par 1 and selected antibodies in the immunohistological distinction of hepatocellular carcinoma from cholangiocarcinoma, combined tumours and metastatic carcinoma. Histopathology. 1998;33:318–324.PubMedCrossRef
12.
Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature. 2001;414:105–111.PubMedCrossRef
13.
Alison MR. Liver stem cells: Implications for hepatocarcinogenesis. Stem Cell Rev. 2005;1:253–260.PubMedCrossRef
14.
Wu XZ, Chen D. Origin of hepatocellular carcinoma: role of stem cells. J Gastroenterol Hepatol. 2006;21:1093–1098.PubMedCrossRef
15.
Fujii H, Zhu XG, Matsumoto T, et al. Genetic classification of combined hepatocellular-cholangiocarcinoma. Hum Pathol. 2000;31:1011–1017.PubMedCrossRef
16.
Yano H, Iemura A, Haramaki M, et al. A human combined hepatocellular and cholangiocarcinoma cell line (KMCH-2) that shows the features of hepatocellular carcinoma or cholangiocarcinoma under different growth conditions. J Hepatol. 1996;24:413–422.PubMedCrossRef
17.
Woo HG, Lee JH, Yoon JH, et al. Identification of a cholangiocarcinoma-like gene expression trait in hepatocellular carcinoma. Cancer Res. 2010;70:3034–3041.PubMedCrossRef
18.
Zhou YM, Yang JM, Wang B, Xu F, Tong Y, Li DQ. Combined hepatocellular carcinoma and cholangiocarcinoma: a case report and review of the literature. Hepatobiliary Pancreat Dis Int. 2007;6:656–659.PubMed
19.
Taguchi J, Nakashima O, Tanaka M, Hisaka T, Takazawa T, Kojiro M. A clinicopathological study on combined hepatocellular and cholangiocarcinoma. J Gastroenterol Hepatol. 1996;11:758–764.PubMedCrossRef
20.
Kassahun WT, Hauss J. Management of combined hepatocellular and cholangiocarcinoma. Int J Clin Pract. 2008;62:1271–1278.PubMedCrossRef
21.
Choi BI, Han JK, Kim YI, et al. Combined hepatocellular and cholangiocarcinoma of the liver: sonography, CT, angiography, and iodized-oil CT with pathologic correlation. Abdom Imaging. 1994;19(1):43–46.PubMedCrossRef
22.
Sanada Y, Shiozaki S, Aoki H, Takakura N, Yoshida K, Yamaguchi Y. A clinical study of 11 cases of combined hepatocellular-cholangiocarcinoma assessment of enhancement patterns on dynamics computed tomography before resection. Hepatol Res. 2005;32:185–195.PubMedCrossRef
23.
Hashimoto T, Nakamura H, Hori S, et al. MR imaging of mixed hepatocellular and cholangiocellular carcinoma. Abdom Imaging. 1994;19(5):430–432.PubMedCrossRef
24.
Hwang J, Kim YK, Park MJ, et al. Differentiating combined hepatocellular and cholangiocarcinoma from mass-forming intrahepatic cholangiocarcinoma using gadoxetic acid-enhanced MRI. J Magn Reson Imaging. 2012;36:881–889.PubMedCrossRef
25.
Koh KC, Lee H, Choi MS, et al. Clinicopathologic features and prognosis of combined hepatocellular cholangiocarcinoma. Am J Surg. 2005;189:120–125.PubMedCrossRef
26.
Nakamura S, Suzuki S, Sakaguchi T, et al. Surgical treatment of patients with mixed hepatocellular carcinoma and cholangiocarcinoma. Cancer. 1996;78:1671–1676.PubMedCrossRef
27.
Tickoo SK, Zee SY, Obiekwe S, et al. Combined hepatocellular-cholangiocarcinoma: a histopathologic, immunohistochemical, and in situ hybridization study. Am J Surg Pathol. 2002;26:989–997.PubMedCrossRef
28.
Okuda K. Natural history of hepatocellular carcinoma including fibrolamellar and hepato-cholangiocarcinoma variants. J Gastroenterol Hepatol. 2002;17:401–405.PubMedCrossRef
29.
Portolani N, Baiocchi GL, Coniglio A, et al. Intrahepatic cholangiocarcinoma and combined hepatocellular-cholangiocarcinoma: a western experience. Ann Surg Oncol. 2008;15:1880–1890.PubMedCrossRef
30.
Kim JH, Yoon HK, Ko GY, et al. Nonresectable combined hepatocellular carcinoma and cholangiocarcinoma: analysis of the response and prognostic factors after transcatheter arterial chemoembolization. Radiology. 2010;255:270–277.PubMedCrossRef
31.
Sotiropoulos GC. Survival benefit in hepatocellular carcinoma: when an innovative transplant strategy might benefit oncology. Lancet Oncol. 2011;12:611–612.PubMedCrossRef
32.
Sapisochin G, Fidelman N, Roberts JP, Yao FY. Mixed hepatocellular cholangiocarcinoma and intrahepatic cholangiocarcinoma in patients undergoing transplantation for hepatocellular carcinoma. Liver Transpl. 2011;17:934–942.PubMedCrossRef
Metadaten
Titel
Combined Hepatocellular Cholangiocarcinoma: A Case Report and Review of Literature
Publikationsdatum
01.07.2013
Erschienen in
Digestive Diseases and Sciences / Ausgabe 7/2013
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-013-2585-1

Weitere Artikel der Ausgabe 7/2013

Digestive Diseases and Sciences 7/2013 Zur Ausgabe

Original Article

Iron Overload Causes Oxidative Stress and Impaired Insulin Signaling in AML-12 Hepatocytes

Original Article

Expression of Fibroblast Growth Factor 19 Is Associated with Recurrence and Poor Prognosis of Hepatocellular Carcinoma

Review

Helicobacter pylori CagA: A Critical Destroyer of the Gastric Epithelial Barrier

Editorial

Increasing Colorectal Cancer Burden Among Young US Hispanics: Is It Time to Change Current Screening Guidelines?

Editorial

Novel and Validated Approaches for Gastric Emptying Scintigraphy in Patients with Suspected Gastroparesis

Original Article

ERCP with Probe-Based Confocal Laser Endomicroscopy for the Evaluation of Dominant Biliary Stenoses in Primary Sclerosing Cholangitis Patients

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise